12:00 AM
 | 
Apr 22, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Zytiga abiraterone acetate regulatory update

Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) said Zytiga abiraterone from Johnson & Johnson has "significant" additional benefit over "watchful waiting" to treat chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (CRPC) - an indication approved by the European Commission in January (see BioCentury, Jan. 14). IQWiG said watchful waiting includes continuation of prior androgen deprivation...

Read the full 263 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >